TRCT
ENVB icon

Tower Research Capital (TRC)’s Enveric Biosciences ENVB Stock Holding History

Tower Research Capital (TRC)’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.88K Buy
4,984
+3,881
+352% +$9.32K ﹤0.01% 4170
2026
Q1 		$2.14K Sell
1,103
-814
-42% -$2.22K ﹤0.01% 4536
2025
Q4 		$6.96K Buy
1,917
+1,715
+849% +$11.2K ﹤0.01% 4040
2025
Q3 		$1.55K Sell
202
-44
-18% -$577 ﹤0.01% 4763
2025
Q2 		$3.58K Buy
246
+48
+24% +$727 ﹤0.01% 4473
2025
Q1 		$3.3K Buy
198
+149
+304% +$5.16K ﹤0.01% 4436
2024
Q4 		$3.15K Sell
49
-48
-49% -$3.48K ﹤0.01% 4701
2024
Q3 		$8.23K Buy
97
+33
+52% +$3.04K ﹤0.01% 3973
2024
Q2 		$7.17K Sell
64
-4
-6% -$603 ﹤0.01% 4491
2024
Q1 		$12.3K Sell
68
-2
-3% -$385 ﹤0.01% 3493
2023
Q4 		$16.5K Buy
70
+17
+32% +$5.22K ﹤0.01% 3779
2023
Q3 		$22.9K Buy
53
+7
+15% +$3.15K ﹤0.01% 3253
2023
Q2 		$28.1K Sell
46
-32
-41% -$15.6K ﹤0.01% 3086
2023
Q1 		$24K Buy
78
+23
+42% +$9.68K ﹤0.01% 3234
2022
Q4 		$21K Buy
55
+12
+28% +$6.64K ﹤0.01% 3080
2022
Q3 		$32K Buy
43
+38
+760% +$47.8K ﹤0.01% 3541
2022
Q2 		$9K Buy
5
+3
+150% +$6.38K ﹤0.01% 4549
2022
Q1 		$7K Buy
+2
New +$8.84K ﹤0.01% 4715
2021
Q4 		– Hold
0
– -$7K – 6236
2021
Q3 		– Sell
-1
Closed -$19.4K – 4635
2021
Q2 		$12K Buy
+1
New +$21.4K ﹤0.01% 4273

Other funds holding ENVB

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s ENVB Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Enveric Biosciences (ENVB) stake by 352% in Q2 2026, buying an estimated $9.32K and bringing the position to 4,984 shares worth $6.88K. The position accounts for ﹤0.01% of the portfolio, ranked #4170.

Tower Research Capital (TRC) first reported a position in ENVB in Q2 2021 and has held it in 19 quarters since. The position peaked at $32K in Q3 2022. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • Tower Research Capital (TRC) held 4,984 shares of Enveric Biosciences worth $6.88K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,881 Enveric Biosciences shares in Q2 2026, an estimated $9.32K.
  • Enveric Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4170 holding.
  • Tower Research Capital (TRC) first reported a position in Enveric Biosciences in Q2 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Enveric Biosciences position peaked at $32K in Q3 2022.
  • 24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.